Mersana Therapeutics Inc (NAS:MRSN)

$ 2.01 0.17 (9.24%) Market Cap: 246.57 Mil Enterprise Value: 98.35 Mil PE Ratio: 0 PB Ratio: 28.71 GF Score: 39/100

Q2 2024 Mersana Therapeutics Inc Earnings Call Transcript
Aug 13, 2024

$1.35 (-4.93%)

Earnings
Q4 2023 Mersana Therapeutics Inc Earnings Call Transcript
Feb 28, 2024

$4.85 (+13.58%)

Earnings
Mersana Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q3 2023 Mersana Therapeutics Inc Earnings Call Transcript
Nov 07, 2023

$1.34 (-3.60%)

Earnings
Mersana Therapeutics Inc UPLIFT Data Update Call Transcript
Jul 27, 2023
Mersana Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Mersana Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Q1 2023 Mersana Therapeutics Inc Earnings Call Transcript
May 09, 2023

$8 (+7.82%)

Earnings
Q4 2022 Mersana Therapeutics Inc Earnings Call Transcript
Feb 28, 2023

$6.06 (+11.60%)

Earnings
Q3 2022 Mersana Therapeutics Inc Earnings Call Transcript
Nov 07, 2022

$6.64 (-11.94%)

Earnings
Mersana Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
Q2 2022 Mersana Therapeutics Inc Earnings Call Transcript
Aug 08, 2022

$5.25 (+4.17%)

Earnings
Mersana Therapeutics Inc at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) Transcript
Jun 02, 2022
Q1 2022 Mersana Therapeutics Inc Earnings Call Transcript
May 09, 2022

$3.18 (-13.35%)

Earnings
Q4 2021 Mersana Therapeutics Inc Earnings Call Transcript
Feb 28, 2022

$4.39 (+7.33%)

Earnings
Mersana Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2022
Mersana Therapeutics Inc at Stifel Healthcare Conference (Virtual) Transcript
Nov 17, 2021
Q3 2021 Mersana Therapeutics Inc Earnings Call Transcript
Nov 09, 2021

$9.52 (-0.94%)

Earnings
Mersana Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2021
Mersana Therapeutics Inc UpRi Clinical Data Update Call Transcript
Sep 10, 2021
Q2 2021 Mersana Therapeutics Inc Earnings Call Transcript
Aug 06, 2021

$12.37 (+2.06%)

Earnings
Q1 2021 Mersana Therapeutics Inc Earnings Call Transcript
May 10, 2021

$14.92 (-3.24%)

Earnings
Mersana Therapeutics Inc Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path - Corporate Call Transcript
Apr 16, 2021
Q4 2020 Mersana Therapeutics Inc Earnings Call Transcript
Feb 26, 2021

$18.18 (-1.03%)

Earnings
Mersana Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Mersana Therapeutics, Inc. - Special Call Transcript
Jan 05, 2021
Mersana Therapeutics, Inc. - Special Call Transcript
Nov 16, 2020
Mersana Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 11, 2020
Q3 2020 Mersana Therapeutics Inc Earnings Call Transcript
Nov 09, 2020

$22.92 (+2.41%)

Earnings
Mersana Therapeutics, Inc. - Special Call Transcript
Sep 17, 2020
Q2 2020 Mersana Therapeutics Inc Earnings Call Transcript
Aug 07, 2020

$20.27 (-0.98%)

Earnings
Mersana Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 12, 2020
Mersana Therapeutics, Inc. - Special Call Transcript
May 27, 2020
Q1 2020 Mersana Therapeutics Inc Earnings Call Transcript
May 08, 2020

$9.81 (-2.10%)

Earnings
Mersana Therapeutics, Inc. - Special Call Transcript
Mar 30, 2020
Q4 2019 Mersana Therapeutics Inc Earnings Call Transcript
Feb 28, 2020

$8.66 (-1.03%)

Earnings
Mersana Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
Q3 2019 Mersana Therapeutics Inc Earnings Call Transcript
Nov 06, 2019

$1.98 (+7.03%)

Earnings
Q2 2019 Mersana Therapeutics Inc Earnings Call Transcript
Aug 08, 2019

$3.16 (+3.95%)

Earnings
Q1 2019 Mersana Therapeutics Inc Earnings Call Transcript
May 09, 2019

$5.91 (+5.54%)

Earnings
Q4 2018 Mersana Therapeutics Inc Earnings Call Transcript
Mar 08, 2019

$4.52 (+7.11%)

Earnings

Mersana Therapeutics, Inc. - Special Call Transcript

May 27, 2020 / 12:00PM GMT

Release Date Price: $18.19 (+69.05%)

Transcript

Operator

Good morning, and welcome to the Mersana Therapeutics conference call to review interim XMT-1536 Phase I dose expansion data. (Operator Instructions)

I would now like to turn the call over to Sarah Carmody, Executive Director, Investor Relations and Corporate Communications. Please proceed.

Sarah Carmody

Mersana Therapeutics, Inc. - Executive Director of IR & Corporate Communications

Good morning, and welcome to our call. Earlier this morning, we issued a press release providing interim data from the ongoing expansion portion of our Phase I study of XMT-1536. This release as well as the slides we will present today are available on the Investors & Media section of our website at www.mersana.com. A replay of today's call will also be made available. After our prepared remarks, we will open the call for Q&A.

Before we begin, I'd like to mention that our call will contain forward-looking statements within the meaning of federal securities laws. These are not statements

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.